top of page

Your Gateway to World-
Class CDMO Solutions

From bench to bedside, lab to lives, the Taiwan CDMO Alliance (TCA)
unites the strengths of 17 well-established CDMOs to deliver integrated, cost-efficient, and innovative solutions for global drug development and manufacturing.

Our Track Record

$7.8B

Combined Market Cap

300+

DMF Submitted

800+

CDMO Projects Delivered

0 OAI

 Since 2015

20+

Years QA Experience

About TCA

ABOUT TCA

Making Taiwan Your Partner for Innovation

The Taiwan CDMO Alliance (TCA) is an industry alliance founded by 17 CDMOs under the mission of providing integrated services with comprehensive capabilities.

Unparalleled One-Stop-Shop Experience

With decades of global CDMO expertise, TCA represents one of the world's most mature and comprehensive ecosystems for expediting innovation to patients.

Strategic Hub Location

Located at the heart of Asia, TCA offers proximity to major global markets with seamless supply chain integration and scalable capacity ensuring world-class quality.

Taiwan Map.png
Service & Capabilities

SERVICE & CAPABILITIES

The Full Bloom of Our Capabilities

Purple Flower.png

Peptide

Linker/

Payload

Cytotoxic

Drug
Substance

Hormone

ADC/XDC

Multispecific antibodies

Nucleotide

Steroid

Yellow Flower.png

Lyophyilizaion

Ophthaimic

Injectable

Lipid Formulation

Drug
Product

Semi-solid

Suspension

Oral Solid

Soft-Gel

Pink Flower.png

Pre-Clinical

Alt Source

Lead

Optimization

Life
Cycle

Validation

Phase 1

Phase 2

Phase 3

Commercialization

Working with TCA

WORKING WITH TCA

The 6Cs of TCA Promise

1

Comprehensive

From Preclinical to Commercialization. Small Molecules, Biologics, Peptides, ADC, Solid Oral, Injectable, Lyophilized, Pre-filled Syringe, Ophthalmic, Topical, and more.​

2

Competitiveness

High barrier technologies: Cytotoxic, Steroid, Nano Technology, Spray Dried, Semi-Synthetic. High level of educated workforce.​

​

3

Capacities

Flexibility due to highly developed and cooperative network of domestic suppliers. Rapid scalability and accelerated timelines.​

​

4

Compliance

Maintains Zero Official Action Indicated (OAI) status with FDA. Deep-rooted compliance culture with major global regulatory bodies.

​

5

Cost

Competitive pricing without compromising quality. Equivalent to other Asian providers.​

​

​

6

Care

Customer loyalty and respect for IP. Seamless handoffs for multi-step manufacturing.

​

​

OUR PROCESS

Working Side by Side for Your Project Success

Connect & Screen

  • Network Outreach

  • Needs & Requirements

  • Preliminary Due Diligence

Common Questions

bottom of page